SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.96+1.0%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doc Bones who wrote (418)10/4/1999 8:59:00 AM
From: Biomaven  Read Replies (1) of 52153
 
Doc,

This is an interesting and difficult issue. If the FDA didn't regulate drug trials so closely, this would be precisely what would happen with drugs as well. (To some extent it did happen with some of the early AIDS drugs like AZT, delaying for years conclusive proof of their degree of efficacy). I'm by nature a sort of laissez faire anti-regulation guy, but I actually believe the FDA is on balance a good thing for the industry.

One of the big challenges is getting patients to participate in drug trials at all. One idea that I see now being used is a trial that isn't 50:50 - instead a bigger proportion get the "active" treatment and only a minority the placebo. You probably need a bigger trial to get the same power, but you might get a lot more applicants and you should get better safety data.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News